Silence unveils more PhI data for siRNA drug in new cardiovascular race targeting Lp(a)

Ayisha Sharma

News Reporter

Silence Therapeutics’ siRNA asset showed hints of efficacy in cardiovascular disease patients enrolled in a Phase I trial amid recent readouts from pipeline rivals backed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Silence unveils more PhI data for siRNA drug in new cardiovascular race targeting Lp(a)

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Sanofi's BTK inhibitor again slows MS progression, but liver enzymes continue to be tricky

Lexicon's president to step down as decision date looms; Sarepta welcomes Lilly, GSK vet to board

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Aligos’ trial for oral MASH treatment succeeds, but placebo group shows odd trend

FDA inspectors discover trucks carrying torn-up records leaving Indian generics factory

Breaking down silos with a new quantitative approach to drug development

Si­lence un­veils more PhI da­ta for siR­NA drug in new car­dio­vas­cu­lar race tar­get­ing Lp(a)

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Silence unveils more PhI data for siRNA drug in new cardiovascular race targeting Lp(a)